Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.
Support for Abortion Medication Access and Science
This bill is currently in the early stages of the legislative process after being sent to the House Committee on Energy and Commerce for review. No further actions are scheduled at this time, and the bill is not moving forward. There is no companion bill listed for this measure.
Legislative Progress
This is a non-binding resolution used to state a political position rather than change the law. It lacks the bipartisan support needed to move forward in a divided Congress.
Key Points
- This resolution expresses the opinion of the House of Representatives that the abortion pill mifepristone is safe and effective. It states that government rules for this medicine should be based on 25 years of medical research and scientific evidence rather than political interference.
- The proposal highlights that medication abortion accounted for 63 percent of all abortions in the United States in 2023. It argues that the FDA should protect the ability for patients to receive this medicine through the mail or after a telehealth appointment with a doctor.
- Supporters say this action is necessary because many states have banned abortion since the Supreme Court overturned Roe v. Wade. They argue that restricting this medicine hurts people in rural areas, those with low incomes, and minority groups who may have trouble traveling to a clinic.
- The resolution points out that while mifepristone has a very strong safety record and is used in over 90 countries, it is still regulated more strictly than 99 percent of other prescription drugs. It calls for these rules to be transparent and fair for all patients.
Impact Analysis
Govbase has not yet run an impact analysis on this legislation.
Milestones
Referred to the House Committee on Energy and Commerce.
Submitted in House
Votes
No votes have been recorded for this legislation yet.
News
No related news coverage found for this legislation yet.
Source Information
Document Type
Congressional Bill
Official Title
Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.
Data Sources
Sponsor
Cosponsors
(12)Analysis generated by AI. Always verify with official sources.